Biology and Therapeutic Properties of Mesenchymal Stem Cells in Leukemia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Mar 13

PMID 38473775

Authors

Cheng-Hsien Wu

Te-Fu Weng

Ju-Pi Li

Kang-Hsi Wu

Affiliations

Soon will be listed here.

Abstract

This comprehensive review delves into the multifaceted roles of mesenchymal stem cells (MSCs) in leukemia, focusing on their interactions within the bone marrow microenvironment and their impact on leukemia pathogenesis, progression, and treatment resistance. MSCs, characterized by their ability to differentiate into various cell types and modulate the immune system, are integral to the BM niche, influencing hematopoietic stem cell maintenance and functionality. This review extensively explores the intricate relationship between MSCs and leukemic cells in acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. This review also addresses the potential clinical applications of MSCs in leukemia treatment. MSCs' role in hematopoietic stem cell transplantation, their antitumor effects, and strategies to disrupt chemo-resistance are discussed. Despite their therapeutic potential, the dual nature of MSCs in promoting and inhibiting tumor growth poses significant challenges. Further research is needed to understand MSCs' biological mechanisms in hematologic malignancies and develop targeted therapeutic strategies. This in-depth exploration of MSCs in leukemia provides crucial insights for advancing treatment modalities and improving patient outcomes in hematologic malignancies.

Citing Articles

Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.

Li Z, Yao X, Zhang J, Yang J, Ni J, Wang Y Front Immunol. 2024; 15:1403458.

PMID: 39161767 PMC: 11330836. DOI: 10.3389/fimmu.2024.1403458.

References

Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth E, Watson K . Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy. 2010; 12(5):615-25. DOI: 10.3109/14653241003631815. View

Kihira K, Chelakkot V, Kainuma H, Okumura Y, Tsuboya N, Okamura S . Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells. Int J Hematol. 2020; 112(6):795-806. DOI: 10.1007/s12185-020-02981-z. View

Kosmidou A, Tragiannidis A, Gavriilaki E . Myeloid Leukemia of Down Syndrome. Cancers (Basel). 2023; 15(13). PMC: 10340042. DOI: 10.3390/cancers15133265. View

Zhu J, Garrett R, Jung Y, Zhang Y, Kim N, Wang J . Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007; 109(9):3706-12. DOI: 10.1182/blood-2006-08-041384. View

Yagi H, Kitagawa Y . The role of mesenchymal stem cells in cancer development. Front Genet. 2013; 4:261. PMC: 3842093. DOI: 10.3389/fgene.2013.00261. View

Minden M, Ubelhart R, Schneider D, Wossning T, Bach M, Buchner M . Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489(7415):309-12. DOI: 10.1038/nature11309. View

Zhou H, Mak P, Mu H, Mak D, Zeng Z, Cortes J . Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017; 31(10):2065-2074. PMC: 5628102. DOI: 10.1038/leu.2017.87. View

Mojtahedi H, Yazdanpanah N, Rezaei N . Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther. 2021; 12(1):603. PMC: 8684082. DOI: 10.1186/s13287-021-02659-1. View

Chong Y, Liu Y, Lu S, Cai B, Qin H, Chang C . Critical individual roles of the BCR and FGFR1 kinase domains in BCR-FGFR1-driven stem cell leukemia/lymphoma syndrome. Int J Cancer. 2019; 146(8):2243-2254. DOI: 10.1002/ijc.32665. View

10.

Brunning R . Classification of acute leukemias. Semin Diagn Pathol. 2003; 20(3):142-53. DOI: 10.1016/s0740-2570(03)00031-5. View

11.

Tabe Y, Jin L, Iwabuchi K, Wang R, Ichikawa N, Miida T . Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts. Leukemia. 2011; 26(5):883-92. DOI: 10.1038/leu.2011.291. View

12.

Ullah I, Subbarao R, Rho G . Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015; 35(2). PMC: 4413017. DOI: 10.1042/BSR20150025. View

13.

Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B . Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2018; 11(1):11. PMC: 5778754. DOI: 10.1186/s13045-018-0554-z. View

14.

Zhu W, Liu S, Shi Y, Tang Q, Sun J, Bai R . The epidemic of acute lymphoid leukemia in China: current trends and future prediction. Front Oncol. 2023; 13:1195065. PMC: 10313194. DOI: 10.3389/fonc.2023.1195065. View

15.

Yi M, Zhou L, Li A, Luo S, Wu K . Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging (Albany NY). 2020; 12(22):22869-22891. PMC: 7746341. DOI: 10.18632/aging.103982. View

16.

Blair A, White D . Leukemia cell types and agricultural practices in Nebraska. Arch Environ Health. 1985; 40(4):211-4. DOI: 10.1080/00039896.1985.10545920. View

17.

Ma Z, Zhao X, Deng M, Huang Z, Wang J, Wu Y . Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells. Cell Rep. 2019; 26(6):1533-1543.e4. DOI: 10.1016/j.celrep.2019.01.034. View

18.

Cowell J, Qin H, Hu T, Wu Q, Bhole A, Ren M . Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int J Cancer. 2017; 141(9):1822-1829. PMC: 5850950. DOI: 10.1002/ijc.30848. View

19.

Guo Y, Wang W, Sun H . A systematic review and meta-analysis on the risk factors of acute myeloid leukemia. Transl Cancer Res. 2022; 11(4):796-804. PMC: 9091028. DOI: 10.21037/tcr-22-27. View

20.

Boulais P, Frenette P . Making sense of hematopoietic stem cell niches. Blood. 2015; 125(17):2621-9. PMC: 4408288. DOI: 10.1182/blood-2014-09-570192. View